Total Payments
$69,054
2024 Payments
$2,858
Companies
22
Transactions
264
Medicare Patients
5,327
Medicare Billing
$469,650
Payment Breakdown by Category
Other$50,800 (73.6%)
Food & Beverage$13,544 (19.6%)
Travel$3,066 (4.4%)
Consulting$1,500 (2.2%)
Education$143.24 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $50,800 | 25 | 73.6% |
| Food and Beverage | $13,544 | 198 | 19.6% |
| Travel and Lodging | $3,066 | 30 | 4.4% |
| Consulting Fee | $1,500 | 4 | 2.2% |
| Education | $143.24 | 7 | 0.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $32,611 | 66 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $23,090 | 36 | $0 (2024) |
| Abbott Laboratories | $3,772 | 35 | $0 (2024) |
| Boston Scientific Corporation | $3,290 | 32 | $0 (2024) |
| Merck Sharp & Dohme LLC | $1,422 | 15 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $1,191 | 20 | $0 (2024) |
| BIOTRONIK INC. | $976.57 | 9 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $710.41 | 9 | $0 (2024) |
| Medtronic Vascular, Inc. | $401.79 | 5 | $0 (2019) |
| Novartis Pharmaceuticals Corporation | $349.45 | 13 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,858 | 48 | Boston Scientific Corporation ($510.25) |
| 2023 | $1,308 | 27 | AstraZeneca Pharmaceuticals LP ($354.63) |
| 2022 | $1,104 | 16 | Boston Scientific Corporation ($430.84) |
| 2021 | $747.72 | 7 | Abbott Laboratories ($267.74) |
| 2020 | $1,045 | 4 | PFIZER INC. ($700.00) |
| 2019 | $6,112 | 23 | PFIZER INC. ($2,910) |
| 2018 | $17,565 | 46 | E.R. Squibb & Sons, L.L.C. ($8,429) |
| 2017 | $38,313 | 93 | PFIZER INC. ($21,068) |
All Payment Transactions
264 individual payment records from CMS Open Payments — Page 1 of 11
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $24.03 | General |
| Category: Cardiovascular | ||||||
| 12/13/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $44.32 | General |
| 12/11/2024 | Celgene Corporation | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $19.69 | General |
| Category: Cardiovascular | ||||||
| 12/03/2024 | Philips North America LLC | (CK4) MCOT (Device) | Food and Beverage | Cash or cash equivalent | $26.25 | General |
| Category: Medical Device | ||||||
| 12/03/2024 | Abbott Laboratories | JOT DX (Device) | Food and Beverage | In-kind items and services | $24.09 | General |
| Category: Cardiac Rhythm Management | ||||||
| 12/03/2024 | Abbott Laboratories | JOT DX (Device) | Food and Beverage | In-kind items and services | $2.89 | General |
| Category: Cardiac Rhythm Management | ||||||
| 12/02/2024 | Abbott Laboratories | JOT DX (Device) | Food and Beverage | In-kind items and services | $159.61 | General |
| Category: Cardiac Rhythm Management | ||||||
| 12/02/2024 | Abbott Laboratories | JOT DX (Device) | Food and Beverage | In-kind items and services | $78.34 | General |
| Category: Cardiac Rhythm Management | ||||||
| 11/26/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $23.85 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/21/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $14.05 | General |
| Category: Cardiovascular | ||||||
| 11/20/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $135.00 | General |
| Category: Cardiovascular | ||||||
| 11/20/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $20.75 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 11/13/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: DIABETES | ||||||
| 11/06/2024 | Celgene Corporation | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $25.81 | General |
| Category: Cardiovascular | ||||||
| 11/06/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $13.93 | General |
| Category: Cardiovascular | ||||||
| 10/23/2024 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | LifeVest (Device) | Food and Beverage | Cash or cash equivalent | $123.26 | General |
| Category: Electromedical and Electrotherapeutic Apparatus | ||||||
| 10/09/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $124.35 | General |
| 09/25/2024 | Boston Scientific Corporation | WATCHMAN FLX (Device) | Food and Beverage | In-kind items and services | $130.38 | General |
| Category: WATCHMAN FLX_IC | ||||||
| 09/24/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $19.74 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 09/18/2024 | Boston Scientific Corporation | — | Food and Beverage | In-kind items and services | $141.86 | General |
| 09/17/2024 | Celgene Corporation | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $25.27 | General |
| Category: Cardiovascular | ||||||
| 08/28/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $23.18 | General |
| Category: DIABETES | ||||||
| 08/27/2024 | Philips North America LLC | (CK7) Extended Holter (Device) | Food and Beverage | Cash or cash equivalent | $33.50 | General |
| Category: Medical Device | ||||||
| 08/06/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $17.64 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 07/31/2024 | PFIZER INC. | VYNDAQEL (Drug) | Food and Beverage | In-kind items and services | $22.17 | General |
| Category: CARDIOVASCULAR | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 11 | 900 | 2,209 | $521,387 | $106,315 |
| 2022 | 10 | 954 | 1,946 | $469,041 | $99,318 |
| 2021 | 16 | 1,745 | 2,721 | $480,428 | $120,551 |
| 2020 | 18 | 1,728 | 3,269 | $628,409 | $143,466 |
Total Patients
5,327
Total Services
10,145
Medicare Billing
$469,650
Procedure Codes
55
All Medicare Procedures & Services
55 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 274 | 630 | $333,593 | $67,522 | 20.2% |
| 93294 | Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | Office | 2023 | 124 | 364 | $44,227 | $9,054 | 20.5% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 281 | 587 | $36,089 | $7,407 | 20.5% |
| 93297 | Evaluation of implantable heart and blood vessel monitoring system, remote up to 30 days | Office | 2023 | 38 | 283 | $29,977 | $6,303 | 21.0% |
| 93280 | Programming of dual lead pacemaker system | Office | 2023 | 60 | 65 | $21,854 | $4,415 | 20.2% |
| 93295 | Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | Office | 2023 | 42 | 111 | $16,415 | $3,473 | 21.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 14 | 14 | $12,838 | $2,365 | 18.4% |
| 93298 | Evaluation of cardiac rhythm monitor system, remote up to 30 days | Office | 2023 | 20 | 102 | $10,930 | $2,341 | 21.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 22 | 25 | $9,414 | $2,145 | 22.8% |
| 93279 | Programming of single lead pacemaker system | Office | 2023 | 14 | 17 | $4,914 | $1,034 | 21.1% |
| 93248 | Heart rhythm review and interpretation of continous external ekg over 8-15 days | Office | 2023 | 11 | 11 | $1,135 | $256.30 | 22.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 278 | 516 | $274,850 | $57,023 | 20.7% |
| 93294 | Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | Office | 2022 | 127 | 307 | $38,274 | $8,572 | 22.4% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2022 | 286 | 493 | $30,487 | $6,520 | 21.4% |
| 93297 | Evaluation of implantable heart and blood vessel monitoring system, remote up to 30 days | Office | 2022 | 59 | 254 | $27,960 | $6,308 | 22.6% |
| 93280 | Programming of dual lead pacemaker system | Office | 2022 | 68 | 80 | $27,792 | $6,001 | 21.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 41 | 54 | $20,611 | $4,251 | 20.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 18 | 18 | $16,848 | $3,394 | 20.1% |
| 93295 | Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | Office | 2022 | 40 | 88 | $13,601 | $3,035 | 22.3% |
| 93298 | Evaluation of cardiac rhythm monitor system, remote up to 30 days | Office | 2022 | 22 | 116 | $12,769 | $2,881 | 22.6% |
| 93279 | Programming of single lead pacemaker system | Office | 2022 | 15 | 20 | $5,848 | $1,333 | 22.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 326 | 625 | $256,875 | $66,485 | 25.9% |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | Office | 2021 | 12 | 46 | $40,480 | $10,671 | 26.4% |
| 93280 | Evaluation, testing, and programming adjustment of permanent dual lead pacemaker system with physician analysis, review, and report | Office | 2021 | 91 | 116 | $25,984 | $8,202 | 31.6% |
| 93000 | Routine ekg using at least 12 leads including interpretation and report | Office | 2021 | 332 | 586 | $39,262 | $7,559 | 19.3% |
About Dr. Anthony Mercando, MD
Dr. Anthony Mercando, MD is a Cardiovascular Disease healthcare provider based in Scarsdale, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/11/2006. The National Provider Identifier (NPI) number assigned to this provider is 1528070505.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Anthony Mercando, MD has received a total of $69,054 in payments from pharmaceutical and medical device companies, with $2,858 received in 2024. These payments were reported across 264 transactions from 22 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($50,800).
As a Medicare-enrolled provider, Mercando has provided services to 5,327 Medicare beneficiaries, totaling 10,145 services with total Medicare billing of $469,650. Data is available for 4 years (2020–2023), covering 55 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Scarsdale, NY
- Active Since 08/11/2006
- Last Updated 10/16/2013
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1528070505
Products in Payments
- ELIQUIS (Drug) $54,552
- SCS leads (Device) $1,538
- VYNDAQEL (Drug) $954.22
- WATCHMAN (Device) $872.58
- BRILINTA (Drug) $791.08
- CRT-Ds (Device) $721.43
- GENERAL THERAPIES (Device) $715.17
- JARDIANCE (Drug) $710.41
- WATCHMAN Access System (Device) $487.23
- WATCHMAN FLX (Device) $402.29
- FARXIGA (Drug) $359.47
- Reveal LINQ (Device) $278.21
- AVEIR (Device) $275.24
- CAMZYOS (Drug) $274.45
- JOT DX (Device) $264.93
- Confirm Rx (Device) $263.21
- LEQVIO (Drug) $192.67
- Acticor 7 VR-T DX (Device) $190.57
- LATITUDE (Device) $187.60
- Vascepa (Drug) $172.58
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Scarsdale
Dr. Daniel Lerner, M.d, M.D
Cardiovascular Disease — Payments: $470,860
Cardiovascular Disease $470,860
Dr. Srirama Kalapatapu, M.d, M.D
Cardiovascular Disease — Payments: $185,044
Cardiovascular Disease $185,044
Dr. Ari Paley, M.d, M.D
Cardiovascular Disease — Payments: $25,362
Cardiovascular Disease $25,362
Dr. Sanjay Naik, M.d, M.D
Cardiovascular Disease — Payments: $23,287
Cardiovascular Disease $23,287
Dr. Amit Chhabra, M.d, M.D
Cardiovascular Disease — Payments: $16,979
Cardiovascular Disease $16,979
Dr. Howard Chester, M.d, M.D
Cardiovascular Disease — Payments: $2,207
Cardiovascular Disease $2,207